Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors.

"Competing interests JCT reports a consulting or advisory role for AstraZeneca and research funding to institution from Delfi Diagnostics and Incyte. ELC reports a consulting or advisory role for Bristol Myers Squibb, honoraria from AstraZeneca, Imedex, Guardant Health and Dartmouth Health and research funding to institution from Merck, Janssen, Becton Dickinson, NCCN, United Health Group, Parker Institute for Cancer Immunotherapy, AstraZeneca, Chip Diagnostics, C2i genomics, and Tempus. CA reports a consulting or advisory role for Genentech, Lilly, Celgene, Merck Sharp & Dohme, AstraZeneca, Blueprint Genetics, Shionogi, Daiichi Sankyo/Astra Zeneca, Sanofi/ Regeneron, Eisai, BeiGene, Turning Point Therapeutics, Pfizer, Janssen, Boehringer Ingelheim and research funding to institution from Genentech/Roche, Incyte, Macrogenics, Merck Sharp & Dohme, and AstraZeneca. DGS reports no competing interests."

"Funding JCT is supported by the National Cancer Institute grant K08 CA234335. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH."